ArticleFrontiers in pediatrics2026
Comparison of the therapeutic performance of macrolide antibiotics on macrolide-resistant or macrolide-susceptible Mycoplasma pneumoniae pneumonia children.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This research aims to investigate the performance of macrolide antibiotics for the treatment of Mycoplasma pneumoniae pneumonia (MPP) in children with or without Mycoplasma pneumoniae (MP) resistance genes. Methods: This retrospective study enrolled pediatric MPP patients admitted to the Department of Pediatrics at the hospital between January 2023 and December 2023. Macrolide resistance genes in MP were tested using throat swab and bronchoalveolar lavage fluid samples, and patients were classified into the macrolide-resistant MP (MRMP) group and the macrolide-susceptible MP (MSMP) group based on the results of v-domain point mutations. After sampling, all patients received standard macrolide treatment. The baseline characteristics and laboratory examination results were documented and compared. Results: A total of 217 MPP patients were included, among these patients, 188 with v-domain point mutations (all A2063 G point mutation) were classified as MRMP (99 males, 5.84 ± 2.81 years) with an MRMP rate of 86.6%, the remaining 29 were classified as MSMP (14 males, 6.79 ± 4.08 years). No significant difference in baseline characteristics was observed between the patients of the two groups. While the MP DNA load was higher in both throat swabs (3.97 ± 0.64 vs. 3.65 ± 0.77; Conclusion: MP DNA load and the duration of macrolide use are higher in MRMP patients, while no significant difference was observed between the prevalence of adverse events and clinical characteristics after treatment, indicating that macrolide treatment demonstrates comparable clinical effectiveness in both MRMP and MSMP patients. However, the association between MP DNA load and duration of macrolide use should be further evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.